Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial
Open Access
- 12 November 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medicine
- Vol. 7 (1), 70
- https://doi.org/10.1186/1741-7015-7-70
Abstract
High dose oral ascorbic acid substantially improved myelination and locomotor function in a Charcot-Marie-Tooth type 1A mouse model. A phase II study was warranted to investigate whether high dose ascorbic acid also has such a substantial effect on myelination in Charcot-Marie-Tooth type 1A patients and whether this treatment is safe.Keywords
This publication has 28 references indexed in Scilit:
- The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up studyBrain, 2009
- Neuropathy progression in Charcot-Marie-Tooth disease type 1ANeurology, 2008
- Ascorbic acid inhibits PMP22 expression by reducing cAMP levelsNeuromuscular Disorders, 2007
- Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy IaZeitschrift für Neurologie, 2004
- PMP22 overexpression causes dysmyelination in miceBrain, 2002
- Clinico-electrophysiological correlation of extensor digitorum brevis muscle atrophy in children with Charcot–Marie–Tooth disease 1A duplicationNeuromuscular Disorders, 2000
- Charcot-Marie-Tooth disease type 1A with 17p duplication in infancy and early childhoodNeurology, 1998
- Longitudinal studies of the duplication form of Charcot-Marie-Tooth polyneuropathyMuscle & Nerve, 1996
- Estimation of the Mutation Frequencies in Charcot-Marie-Tooth Disease Type 1 and Hereditary Neuropathy with Liability to Pressure Palsies: A European Collaborative StudyEuropean Journal of Human Genetics, 1996
- Early morphological features in dominantly inherited demyelinating motor and sensory neuropathy (HMSN type I)Journal of the Neurological Sciences, 1992